Ipsen appoints Dr. Alexandre Lebeaut as EVP, R&D, and chief scientific officer

Tuesday, April 18, 2017

Ipsen announced the appointment of Dr. Alexandre Lebeaut as executive vice president, R&D, and chief scientific officer, effective immediately. Dr. Lebeaut will report directly to David Meek, CEO of Ipsen, and serve on the executive leadership team. Dr. Lebeaut joined Ipsen in 2013 as senior vice president, chief development officer, Global Drug Development and was appointed interim head of R&D in December 2016.

[Read More]

Axcan acquires Mpex

Thursday, April 14, 2011

Two pharmaceutical companies, Mpex and Axcan, have entered into an agreement in which Axcan will acquire all of the outstanding shares of Mpex and its lead product candidate, Aeroquin.  An aerosol formulation of levofloxacin, Aeroquin is currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.

[Read More]